Advertisement
Advertisement
HALO
Halozyme Therapeutics, Inc.
130.03
USDSponsored
+1.53
+1.19%
Oct 28, 16:00 UTC -4
Closed
Pre-Market
131.82
+1.79
+1.38%
Halozyme Therapeutics, Inc. (HALO) Earnings
HALO Earnings Reports
Positive Surprise Ratio
HALO beat 32 of 43 last estimates.
74%
Next Report
Next Week
Date of Next Report
Nov 05, 2026
Estimate for Q3 26 (Revenue/ EPS)
$500.66M
/$2.39
Implied change from Q2 26 (Revenue/ EPS)
+4.09%
/+5.29%
Implied change from Q3 25 (Revenue/ EPS)
+41.33%
/+38.95%
Halozyme Therapeutics, Inc. earnings per share and revenue
On Aug 06, 2026, HALO reported earnings of 2.27 USD per share (EPS) for Q2 26, beating the estimate of 1.87 USD, resulting in a 21.75% surprise. Revenue reached 481.00 million, compared to an expected 415.64 million, with a 15.72% difference. The market reacted with a +20.24% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 6 analysts forecast an EPS of 2.39 USD, with revenue projected to reach 500.66 million USD, implying an increase of 5.29% EPS, and increase of 4.09% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Bristol-Myers Squibb Co.
Report Date
Oct 29, 2026 For Q3 26
Estimate
$1.20
Actual
$1.35
Surprise
+11.66%
Alnylam Pharmaceuticals, Inc.
Report Date
Oct 29, 2026 For Q3 26
Estimate
$1.65
Actual
$16.26
Surprise
+885.34%
Incyte Genomics Inc
Report Date
Oct 29, 2026 For Q3 26
Estimate
-$3.92
Actual
-$3.60
Surprise
+8.33%
Insmed, Inc.
Report Date
Oct 29, 2026 For Q3 26
Estimate
-$0.38
Actual
-$0.46
Surprise
-19.82%
Kymera Therapeutics, Inc. Common Stock
Report Date
Oct 29, 2026 For Q3 26
Estimate
-$1.29
Actual
-$1.32
Surprise
-2.17%
Ligand Pharmaceuticals Inc.
Report Date
Oct 29, 2026 For Q3 26
Estimate
$2.42
Actual
$2.67
Surprise
+9.91%
Fortrea Holdings Inc. Common Stock
Report Date
Oct 29, 2026 For Q3 26
Estimate
$0.22
Actual
$0.28
Surprise
+26.53%
NeoGenomics, Inc.
Report Date
Oct 28, 2026 For Q3 26
Estimate
$0.05
Actual
$0.07
Surprise
+27.50%
NovoCure Limited Ordinary Shares
Report Date
Oct 29, 2026 For Q3 26
Estimate
-$0.24
Actual
-$0.09
Surprise
+63.88%
Phathom Pharmaceuticals, Inc. Common Stock
Report Date
Oct 29, 2026 For Q3 26
Estimate
-$0.14
Actual
$0.04
Surprise
+128.27%
FAQ
What were Halozyme Therapeutics, Inc.'s earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Halozyme Therapeutics, Inc. reported EPS of $2.27, beating estimates by 21.75%, and revenue of $481.00M, 15.72% above expectations.
How did the market react to Halozyme Therapeutics, Inc.'s Q2 2026 earnings?
The stock price moved up 20.24%, changed from $85.76 before the earnings release to $103.12 the day after.
When is Halozyme Therapeutics, Inc. expected to report next?
The next earning report is scheduled for Nov 05, 2026.
What are the forecasts for Halozyme Therapeutics, Inc.'s next earnings report?
Based on 6
analysts, Halozyme Therapeutics, Inc. is expected to report EPS of $2.39 and revenue of $500.66M for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.